

# Edward J Pavlik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5283627/publications.pdf>

Version: 2024-02-01

116  
papers

4,239  
citations

134610

34  
h-index

129628

63  
g-index

118  
all docs

118  
docs citations

118  
times ranked

2361  
citing authors

#	ARTICLE	IF	CITATIONS
1	Significance of Pelvic Fluid Observed during Ovarian Cancer Screening with Transvaginal Sonogram. <i>Diagnostics</i> , 2022, 12, 144.	1.3	1
2	Ultrasonographic Visualization of the Ovaries to Detect Ovarian Cancer According to Age, Menopausal Status and Body Type. <i>Diagnostics</i> , 2022, 12, 128.	1.3	4
3	Subsequent Ultrasonographic Non-Visualization of the Ovaries Is Hastened in Women with Only One Ovary Visualized Initially. <i>Healthcare (Switzerland)</i> , 2022, 10, 433.	1.0	2
4	Perspectives on Ovarian Cancer 1809 to 2022 and Beyond. <i>Diagnostics</i> , 2022, 12, 791.	1.3	7
5	Clinicopathological effects of body composition measurements for patients with endometrial cancer. <i>Minerva Ginecologica</i> , 2021, 72, 430-435.	0.8	0
6	Disease-Specific Survival of Type I and Type II Epithelial Ovarian Cancers—Stage Challenges Categorical Assignments of Indolence & Aggressiveness. <i>Diagnostics</i> , 2020, 10, 56.	1.3	11
7	Assessing the Costs of Screening for Ovarian Cancer in the United States: An Evolving Analysis. <i>Diagnostics</i> , 2020, 10, 67.	1.3	5
8	Clinical Factors Associated with Longer Hospital Stay Following Ovarian Cancer Surgery. <i>Healthcare (Switzerland)</i> , 2019, 7, 85.	1.0	8
9	Psychological Response to a False Positive Ovarian Cancer Screening Test Result: Distinct Distress Trajectories and Their Associated Characteristics. <i>Diagnostics</i> , 2019, 9, 128.	1.3	3
10	Simple Adnexal Cysts: SRU Consensus Conference Update on Follow-up and Reporting. <i>Radiology</i> , 2019, 293, 359-371.	3.6	47
11	Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening. <i>Obstetrics and Gynecology</i> , 2018, 132, 1091-1100.	1.2	25
12	Ovarian Cancer Screening: Lessons about Effectiveness. <i>Diagnostics</i> , 2018, 8, 1.	1.3	32
13	Demographic, clinical, dispositional, and social-environmental characteristics associated with psychological response to a false positive ovarian cancer screening test: a longitudinal study. <i>Journal of Behavioral Medicine</i> , 2018, 41, 277-288.	1.1	2
14	First International Consensus Report on Adnexal Masses: Management Recommendations. <i>Journal of Ultrasound in Medicine</i> , 2017, 36, 849-863.	0.8	72
15	Affective, cognitive and behavioral outcomes associated with a false positive ovarian cancer screening test result. <i>Journal of Behavioral Medicine</i> , 2017, 40, 803-813.	1.1	5
16	Complications from Surgeries Related to Ovarian Cancer Screening. <i>Diagnostics</i> , 2017, 7, 16.	1.3	5
17	Ten Important Considerations for Ovarian Cancer Screening. <i>Diagnostics</i> , 2017, 7, 22.	1.3	5
18	Ultrasound Monitoring of Extant Adnexal Masses in the Era of Type 1 and Type 2 Ovarian Cancers: Lessons Learned From Ovarian Cancer Screening Trials. <i>Diagnostics</i> , 2017, 7, 25.	1.3	3

#	ARTICLE	IF	CITATIONS
19	Symptoms Relevant to Surveillance for Ovarian Cancer. <i>Diagnostics</i> , 2017, 7, 18.	1.3	5
20	Probability of Fallopian Tube and Ovarian Detection with Transvaginal Ultrasonography in Normal Women. <i>Women's Health</i> , 2016, 12, 303-311.	0.7	12
21	Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening. <i>Women's Health</i> , 2016, 12, 475-479.	0.7	9
22	First Year Participation in the Affordable Care Act: Costs and Accessibility to Gynecologic Oncology. <i>Women's Health</i> , 2015, 11, 865-882.	0.7	0
23	Ultrasound follow up of an adnexal mass has the potential to save lives. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 657-657.e1.	0.7	12
24	Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer. <i>Journal of Oncology</i> , 2014, 2014, 1-6.	0.6	2
25	Serial ultrasonographic evaluation of ovarian abnormalities with a morphology index. <i>Gynecologic Oncology</i> , 2014, 135, 8-12.	0.6	29
26	Metrics of the gynecologic oncology literature focused on cited utilization and costs. <i>Gynecologic Oncology</i> , 2014, 132, 423-427.	0.6	0
27	Early Detection of Ovarian Tumors Using Ultrasound. <i>Women's Health</i> , 2013, 9, 39-57.	0.7	18
28	Frequency and Disposition of Ovarian Abnormalities Followed With Serial Transvaginal Ultrasonography. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 793-794.	0.2	0
29	Frequency and Disposition of Ovarian Abnormalities Followed With Serial Transvaginal Ultrasonography. <i>Obstetrics and Gynecology</i> , 2013, 122, 210-217.	1.2	77
30	Ovarian Cancer Screening—What Women Want. <i>International Journal of Gynecological Cancer</i> , 2012, 22, S21-S23.	1.2	6
31	Ovarian Cancer Screening. <i>Clinical Obstetrics and Gynecology</i> , 2012, 55, 43-51.	0.6	32
32	Long-Term Survival of Women With Epithelial Ovarian Cancer Detected by Ultrasonographic Screening. <i>Obstetrics and Gynecology</i> , 2011, 118, 1212-1221.	1.2	102
33	Receipt of a False Positive Test Result During Routine Screening for Ovarian Cancer: A Teachable Moment?. <i>Journal of Clinical Psychology in Medical Settings</i> , 2011, 18, 70-77.	0.8	6
34	Response to an abnormal ovarian cancer-screening test result: Test of the social cognitive processing and cognitive social health information processing models. <i>Psychology and Health</i> , 2011, 26, 383-397.	1.2	13
35	Predicting Risk of Malignancy in Adnexal Masses. <i>Obstetrics and Gynecology</i> , 2010, 115, 687-694.	1.2	69
36	Risk of malignancy in sonographically confirmed septated cystic ovarian tumors. <i>Gynecologic Oncology</i> , 2010, 118, 278-282.	0.6	47

#	ARTICLE	IF	CITATIONS
37	The search for meaningâ€”Symptoms and transvaginal sonography screening for ovarian cancer. <i>Cancer</i> , 2009, 115, 3689-3698.	2.0	33
38	Long-Term Survival and Cost of Treatment in Patients with Stage IIIC Epithelial Ovarian Cancer. <i>Current Women's Health Reviews</i> , 2009, 5, 44-50.	0.1	9
39	Testosterone Treatment in Women â€” An Overview. <i>Current Women's Health Reviews</i> , 2009, 5, 29-43.	0.1	8
40	Validity of Self-Reports of Return for Routine Repeat Screening in an Ovarian Cancer Screening Program: Table 1.. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 490-493.	1.1	4
41	Abnormal Ovarian Cancer Screening Test Result. <i>Journal of Psychosocial Oncology</i> , 2007, 25, 1-18.	0.6	6
42	Ovarian cancer screening with annual transvaginal sonography. <i>Cancer</i> , 2007, 109, 1887-1896.	2.0	195
43	The treatment of lateral T1 and T2 squamous cell carcinomas of the vulva confined to the labium majus or minus. <i>Gynecologic Oncology</i> , 2007, 104, 390-395.	0.6	33
44	Primary appendiceal cancer: Gynecologic manifestations and treatment options. <i>Gynecologic Oncology</i> , 2007, 104, 602-606.	0.6	30
45	Factors associated with return for routine annual screening in an ovarian cancer screening program. <i>Gynecologic Oncology</i> , 2007, 104, 695-701.	0.6	10
46	Psychological and behavioral impact of receipt of a â€œnormalâ€•ovarian cancer screening test. <i>Preventive Medicine</i> , 2006, 42, 463-470.	1.6	10
47	The accuracy of examination under anesthesia and transvaginal sonography in evaluating ovarian size. <i>Gynecologic Oncology</i> , 2005, 99, 400-403.	0.6	38
48	The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). <i>Gynecologic Oncology</i> , 2005, 99, 557-563.	0.6	66
49	ON THOSE WHO CARE FOR WOMEN. <i>Gynecologic Oncology</i> , 2004, 95, 242.	0.6	0
50	Clinical, demographic, and psychological characteristics of new, asymptomatic participants in a transvaginal ultrasound screening program for ovarian cancer. <i>Preventive Medicine</i> , 2004, 39, 315-322.	1.6	15
51	Psychological Response to Test Results in an Ovarian Cancer Screening Program: A Prospective, Longitudinal Study.. <i>Health Psychology</i> , 2004, 23, 622-630.	1.3	32
52	Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigationâ†. <i>Gynecologic Oncology</i> , 2003, 89, 233-235.	0.6	68
53	Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. <i>Gynecologic Oncology</i> , 2003, 91, 46-50.	0.6	138
54	Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. <i>Obstetrics and Gynecology</i> , 2003, 102, 594-599.	1.2	129

#	ARTICLE	IF	CITATIONS
55	Risk of Malignancy in Unilocular Ovarian Cystic Tumors Less Than 10 Centimeters in Diameter. <i>Obstetrics and Gynecology</i> , 2003, 102, 594-599.	1.2	90
56	Relating Ovarian Size to Age, Menopausal Status, and Use of Hormones. <i>Gynecologic Oncology</i> , 2001, 80, 333-334.	0.6	11
57	Continuing participation supports ultrasound screening for ovarian cancer. <i>Ultrasound in Obstetrics and Gynecology</i> , 2000, 15, 354-364.	0.9	15
58	Ovarian Volume Related to Age. <i>Gynecologic Oncology</i> , 2000, 77, 410-412.	0.6	246
59	The Efficacy of Transvaginal Sonographic Screening in Asymptomatic Women at Risk for Ovarian Cancer. <i>Gynecologic Oncology</i> , 2000, 77, 350-356.	0.6	330
60	Transvaginal Sonography as a Screening Method for the Detection of Early Ovarian Cancer. <i>Gynecologic Oncology</i> , 1997, 65, 408-414.	0.6	110
61	Antiestrogen Resistance in Human Breast Cancer. , 1997, , 115-160.		0
62	Antiestrogen Resistance in Human Breast Cancer. , 1997, , 115-160.		0
63	Publication-Quality Labeling of Gels Using Transparency-Mounted Photographs and Word Processing Software. <i>BioTechniques</i> , 1996, 21, 1126-1127.	0.8	0
64	Ovarian cancer screening. <i>Cancer</i> , 1995, 76, 2086-2091.	2.0	83
65	Participation in Transvaginal Ovarian Cancer Screening: Compliance, Correlation Factors, and Costs. <i>Gynecologic Oncology</i> , 1995, 57, 395-400.	0.6	27
66	Ovarian Cancer Screening in Asymptomatic Postmenopausal Women. <i>Obstetrical and Gynecological Survey</i> , 1994, 49, 330-331.	0.2	0
67	Ovarian cancer screening. <i>Cancer</i> , 1993, 71, 1523-1528.	2.0	26
68	Immunohistochemical Staining for CA-125 in Fallopian Tube Carcinomas. <i>Gynecologic Oncology</i> , 1993, 48, 360-363.	0.6	24
69	A Morphology Index Based on Sonographic Findings in Ovarian Cancer. <i>Gynecologic Oncology</i> , 1993, 51, 7-11.	0.6	185
70	Ovarian Cancer Screening in Asymptomatic Postmenopausal Women. <i>Gynecologic Oncology</i> , 1993, 51, 205-209.	0.6	84
71	Images of Estrogen-Receptor-Positive Breast Tumors Produced by Estradiol Labeled With Iodine I 123 at 161±. <i>Archives of Surgery</i> , 1993, 128, 1373.	2.3	26
72	The growth response of BG-1 ovarian carcinoma cells to estradiol, 4OH-tamoxifen, and tamoxifen: Evidence for intrinsic antiestrogen activation. <i>Gynecologic Oncology</i> , 1991, 42, 245-249.	0.6	5

#	ARTICLE	IF	CITATIONS
73	Ovarian cancer screening in asymptomatic postmenopausal women by transvaginal sonography. <i>Cancer</i> , 1991, 68, 458-462.	2.0	130
74	Transvaginal sonography as a screening method for ovarian cancer a report of the first 1000 cases screened. <i>Cancer</i> , 1990, 65, 573-577.	2.0	129
75	The efficacy of laser therapy in the treatment of cervical intraepithelial neoplasia. <i>Gynecologic Oncology</i> , 1990, 36, 79-81.	0.6	13
76	Stage i serous papillary carcinoma of the endometrium. <i>Cancer</i> , 1989, 63, 2224-2228.	2.0	82
77	Transvaginal sonography as a screening method for ovarian cancer. <i>Gynecologic Oncology</i> , 1989, 34, 402-406.	0.6	92
78	Intermolecular engagement of estrogen receptors indicated by the formation of a high molecular weight complex during activation. <i>Biochemistry</i> , 1989, 28, 9741-9749.	1.2	6
79	Small cell carcinoma of the uterine cervix. <i>Cancer</i> , 1988, 62, 1586-1593.	2.0	99
80	Prognostic factors in early vulvar cancer. <i>Gynecologic Oncology</i> , 1988, 31, 43-49.	0.6	52
81	Extensive in Situ Activation of Nuclear Estrogen Receptors after Exposure of Murine Uteri to [3H]Estradiol or [3H]4-Hydroxytamoxifen*. <i>Endocrinology</i> , 1987, 120, 1608-1614.	1.4	4
82	IDENTIFICATION OF A VERY LARGE NUCLEAR ESTROGEN RECEPTOR COMPLEX.. <i>Endocrinology</i> , 1987, 120, 2189-2191.	1.4	3
83	Marked hypodiploidy in blast phase chronic myelogenous leukemia: Report of a case and review of the literature. <i>American Journal of Hematology</i> , 1987, 24, 293-299.	2.0	4
84	The effects of acute administration of cytotoxic anticancer agents on the capacity for subsequent hormonal responses in the mouse uterus. <i>The Journal of Steroid Biochemistry</i> , 1986, 25, 231-237.	1.3	4
85	Proliferation, Esterase Activity, and Propidium Iodide Exclusion in Urologic Tumor Cells After in Vitro Exposure to Chemotherapeutic Agents. <i>Journal of Urology</i> , 1986, 135, 1091-1100.	0.2	3
86	Programming for the DNA analysis of FCM data on an IBM microcomputer. <i>Cytometry</i> , 1986, 7, 93-97.	1.8	4
87	Reply to Dr. van bockstaele. <i>Cytometry</i> , 1986, 7, 396-396.	1.8	0
88	Antagonism to Estradiol in the Mouse: Reduced Entry of Receptors Complexed with 4-Hydroxytamoxifen into a Mg <sup>2+</sup> -Soluble Chromatin Fraction*. <i>Endocrinology</i> , 1986, 118, 1924-1934.	1.4	21
89	Growth of Urinary Transitional Cell Carcinoma Cell Lines in Agar, Agarose and Methyl Cellulose. <i>Journal of Urology</i> , 1985, 134, 985-990.	0.2	2
90	The Prognostic Significance of Lymph-Vascular Space Invasion in Stage I Endometrial Cancer. <i>Obstetrical and Gynecological Survey</i> , 1985, 40, 661.	0.2	0

#	ARTICLE	IF	CITATIONS
91	Dichloro(6-aminoethylaminopurine)platinum(II) and its hydroxy analogues: Synthesis and preliminary evaluation. <i>Inorganica Chimica Acta</i> , 1985, 108, 91-98.	1.2	7
92	The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer. <i>Cancer</i> , 1985, 55, 1753-1757.	2.0	142
93	Steroid receptor analysis by size-exclusion liquid chromatography: considerations for the clinical laboratory.. <i>Clinical Chemistry</i> , 1985, 31, 537-545.	1.5	8
94	Esterase Activity, Exclusion of Propidium Iodide, and Proliferation in Tumor Cells Exposed to Anticancer Agents: Phenomena Relevant to Chemosensitivity Determinations. <i>Cancer Investigation</i> , 1985, 3, 413-426.	0.6	23
95	Hydrodynamic characterizations of estrogen receptors complexed with [3H]-4-hydroxytamoxifen: evidence in support of contrasting receptor transitions mediated by different ligands. <i>Biochemistry</i> , 1985, 24, 8101-8106.	1.2	19
96	Stability of Doxorubicin in Relation to Chemosensitivity Determinations: Loss of Lethality and Retention of Antiproliferative Activity. <i>Cancer Investigation</i> , 1984, 2, 449-458.	0.6	14
97	Estrogenicity of coumestrol in the mouse: fluorescence detection of interaction with estrogen receptors. <i>Biochemistry</i> , 1984, 23, 2565-2572.	1.2	36
98	Visicalcâ,¢ and Visiplotâ,¢ software routines and the analysis of data routinely encountered in steroid biochemistry. <i>Steroids</i> , 1984, 43, 393-405.	0.8	1
99	Immunohistochemical localization of tumor markers in epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1984, 149, 154-158.	0.7	34
100	The proliferation of human tumor cell lines in the presence of different agars, agaroses, and methyl cellulose. <i>In Vitro</i> , 1983, 19, 538-550.	1.2	4
101	Properties of anticancer agents relevant to in vitro determinations of human tumor cell sensitivity. <i>Cancer Chemotherapy and Pharmacology</i> , 1983, 11, 8-15.	1.1	23
102	The Effect of Different Agars, Agaroses and Methyl Cellulose on the in Vitro Proliferation of a Human Urinary Transitional Cell Carcinoma Cell Line. <i>Journal of Urology</i> , 1983, 129, 1254-1257.	0.2	4
103	The intranuclear distribution of rat uterine estrogen receptors determined after nuclease treatment and chromatin fractionation. <i>Molecular and Cellular Endocrinology</i> , 1982, 26, 201-216.	1.6	8
104	Sensitivity to anticancer agents in vitro: Standardizing the cytotoxic response and characterizing the sensitivities of a reference cell line. <i>Gynecologic Oncology</i> , 1982, 14, 243-261.	0.6	15
105	Rapid analysis of estrogen and progesterone receptors using gel-exclusion high-performance liquid chromatography. <i>Biochemistry</i> , 1982, 21, 139-145.	1.2	63
106	Some practical aspects of the separation of estrogen and progesterone receptors by size exclusion high performance liquid chromatography which are relevant to quantitation. <i>The Journal of Steroid Biochemistry</i> , 1982, 17, 553-558.	1.3	24
107	Biochemical markers in the plasma and tumors of patients with gynecologic malignancies. <i>Cancer</i> , 1981, 48, 495-503.	2.0	40
108	Estrogen-binding properties of cytoplasmic and nuclear estrogen receptors in the presence of Triton X-100. <i>The Journal of Steroid Biochemistry</i> , 1980, 13, 1433-1441.	1.3	11

#	ARTICLE	IF	CITATIONS
109	Characterization of Estrogen Receptors and Biological Responses to Estrogen in Human Endometrium. , 1980, , 107-126.		0
110	Localization of estrogen receptors in uterine cells. Experimental Cell Research, 1979, 123, 177-189.	1.2	32
111	Human Endometrial Cells in Primary Tissue Culture: Estrogen Interactions and Modulation of Cell Proliferation*. Journal of Clinical Endocrinology and Metabolism, 1978, 47, 333-344.	1.8	57
112	Effects of estrogen and progesterone on cytoplasmic estrogen receptor and rates of protein synthesis in rat uterus. The Journal of Steroid Biochemistry, 1977, 8, 205-212.	1.3	43
113	Hydroxylapatite assay for estrogen receptors: Increased sensitivity over present receptor assays. The Journal of Steroid Biochemistry, 1976, 7, 357-368.	1.3	128
114	Modulation of estrogen receptors in four different target tissues: Differential effects of estrogen vs progesterone. The Journal of Steroid Biochemistry, 1976, 7, 369-376.	1.3	68
115	Species-characteristic responses to catnip by undomesticated felids. Journal of Chemical Ecology, 1976, 2, 239-253.	0.9	24
116	The Log Odds of Positive Lymph Nodes Predict Survival of Advanced-Stage Endometrial Cancer: A Retrospective Analysis of 3230 Patients in the Surveillance, Epidemiology, and End Results Database. Journal of Gynecologic Surgery, 0, , .	0.0	1